{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:23:48Z","timestamp":1789122228445,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","advancesradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.adro.2024.101577","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:41:48Z","timestamp":1722645708000},"page":"101577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical Outcomes of Proton Beam Therapy for Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Retrospective Study"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9406-5440","authenticated-orcid":false,"given":"Ichiro","family":"Seto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4752-5125","authenticated-orcid":false,"given":"Hisashi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9227-1366","authenticated-orcid":false,"given":"Yoshiaki","family":"Takagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Azami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohisa","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Machida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntao","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nor Shazrina Binti","family":"Sulaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Teranishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2024.101577_bib0001","first-page":"87","article-title":"Global cancer statistic","volume":"2015","author":"Torre","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.adro.2024.101577_bib0002","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/gut.2004.047191","article-title":"Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry","volume":"54","author":"Carpelan-Holmstr\u00f6m","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.adro.2024.101577_bib0003","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/MPA.0b013e318258055c","article-title":"Japan pancreatic cancer registry; 30th year anniversary: Japan Pancreas Society","volume":"41","author":"Egawa","year":"2012","journal-title":"Pancreas"},{"key":"10.1016\/j.adro.2024.101577_bib0004","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/jjco\/hyq169","article-title":"Cancer incidence and incidence rates in Japan in 2005: Based on data from 12 population\u2013based center registries in the Monitoring of Cancer incidence in Japan (MCIJ) project","volume":"41","author":"Matsuda","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.adro.2024.101577_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000267","article-title":"Preoperative\/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages","volume":"7","author":"Gillen","year":"2010","journal-title":"PLoS Med"},{"key":"10.1016\/j.adro.2024.101577_bib0006","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0002-9610(05)80406-4","article-title":"Prognostic indicators for survival after resection of pancreatic adenocarcinoma","volume":"165","author":"Geer","year":"1993","journal-title":"Am J Surg"},{"key":"10.1016\/j.adro.2024.101577_bib0007","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2011.34.8904","article-title":"Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: An Eastern Cooperative Oncology Group trial","volume":"29","author":"Loehrer","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2024.101577_bib0008","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer. A randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2024.101577_bib0009","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/jjco\/hyq011","article-title":"Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG506","volume":"40","author":"Ishii","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.adro.2024.101577_bib0010","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.4143\/crt.2015.400","article-title":"Prognostic Scoring Index for patients with metastatic pancreatic adenocarcinoma","volume":"48","author":"Park","year":"2016","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.adro.2024.101577_bib0011","series-title":"General Rules for the Study of Classification of Pancreatic Cancer","year":"2023"},{"key":"10.1016\/j.adro.2024.101577_bib0012","series-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae), Pancreatic Adenocarcinoma, ver 2","year":"2024"},{"key":"10.1016\/j.adro.2024.101577_bib0013","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.adro.2024.101577_bib0014","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.radonc.2016.03.021","article-title":"ARCII A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer","volume":"119","author":"Wilson","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2024.101577_bib0015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijrobp.2010.01.027","article-title":"Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer","volume":"80","author":"Sudo","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2024.101577_bib0016","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1245\/s10434-017-6322-4","article-title":"Chemotherapy with or without definitive radiation therapy in inoperable pancreatic cancer","volume":"25","author":"Zhong","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.adro.2024.101577_bib0017","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/annonc\/mdn281","volume":"19","author":"Chauffert","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.adro.2024.101577_bib0018","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.radonc.2011.12.029","article-title":"A phase I\/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis","volume":"103","author":"Terashima","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2024.101577_bib0019","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13014-022-02001-w","article-title":"Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: A single-center retrospective study","volume":"17","author":"Ogura","year":"2022","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2024.101577_bib0020","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ijrobp.2015.12.362","article-title":"Carbon ion radiation therapy with concurrent gemcitabine for patients with locally advanced pancreatic cancer","volume":"95","author":"Shinoto","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2024.101577_bib0021","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.pan.2017.07.191","article-title":"Comparison of proton beam radiotherapy and hyper-fractionated accelerated chemoradiotherapy for locally advanced pancreatic cancer","volume":"17","author":"Maemura","year":"2017","journal-title":"Pancreatology"},{"key":"10.1016\/j.adro.2024.101577_bib0022","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20160790","article-title":"Dose escalation study with respiratory-gated carbon-ion scanning radiotherapy using a simultaneous integrated boost for pancreatic cancer: Simulation with four-dimensional computed tomography","volume":"90","author":"Kawashiro","year":"2017","journal-title":"Br J Radiol"},{"key":"10.1016\/j.adro.2024.101577_bib0023","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.radonc.2018.08.026","article-title":"A single institutional experience of combined carbon-ion radiotherapy and chemotherapy for unresectable locally advanced pancreatic cancer","volume":"129","author":"Shinoto","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2024.101577_bib0024","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.radonc.2019.03.012","article-title":"Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer","volume":"136","author":"Hiroshima","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2024.101577_bib0025","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1200\/JCO.2010.33.8038","article-title":"Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: Correlation of Smad4(Dpc4) immunostaining with pattern of disease progression","volume":"29","author":"Crane","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2024.101577_bib0026","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/j.prro.2020.01.012","article-title":"Dose-escalated radiation therapy for pancreatic cancer: A simultaneous integrated boost approach","volume":"10","author":"Koay","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.adro.2024.101577_bib0027","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ijrobp.2023.05.023","article-title":"A multi-institutional phase 2 trial of ablative 5-fraction stereotactic magnetic resonance-guided on-table adaptive radiation therapy for borderline resectable and locally advanced pancreatic cancer","volume":"117","author":"Parikh","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2024.101577_bib0028","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0057","article-title":"Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer","volume":"7","author":"Reyngold","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.adro.2024.101577_bib0029","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221150228","article-title":"Multi-institutional outcomes of patients aged 75 years and older with pancreatic ductal adenocarcinoma treated with 5-fraction ablative stereotactic magnetic resonance image-guided adaptive radiation therapy (A-SMART)","volume":"30","author":"Bryant","year":"2023","journal-title":"Cancer Control"},{"key":"10.1016\/j.adro.2024.101577_bib0030","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/030089160609200603","article-title":"Phase II study of induction chemotherapy with gemcitabine plus 5-fluorouracil followed by gemcitabine-based concurrent chemoradiotherapy for unresectable locally advanced pancreatic cancer","volume":"92","author":"Kurt","year":"2006","journal-title":"Tumori"},{"key":"10.1016\/j.adro.2024.101577_bib0031","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.ijrobp.2006.10.015","article-title":"Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: A phase I-II study","volume":"67","author":"Brade","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2024.101577_bib0032","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1200\/JCO.2006.07.5663","article-title":"Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies","volume":"25","author":"Huguet","year":"2007","journal-title":"J Clin Oncol"},{"issue":"suppl 6","key":"10.1016\/j.adro.2024.101577_bib0033","first-page":"621 PD","article-title":"Randomized phase II study of S-1 and concurrent radiotherapy with versus without induction chemotherapy of gemcitabine for locally advanced pancreatic cancer (LAPC): Final analysis of JCOG1106","volume":"27","author":"Ioka","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.adro.2024.101577_bib0034","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1634\/theoncologist.2014-0394","article-title":"Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer","volume":"20","author":"Tabernero","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.adro.2024.101577_bib0035","first-page":"1479","article-title":"Performance status is an important prognostic factor in second line treatment of pancreaticobiliary adenocarcinoma","volume":"60","author":"Erdogan","year":"2013","journal-title":"Hepato Gastroenterology"},{"key":"10.1016\/j.adro.2024.101577_bib0036","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s10147-012-0474-9","article-title":"Performance status of patients is the major prognostic factor at all stages of pancreatic cancer","volume":"18","author":"Tas","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.adro.2024.101577_bib0037","first-page":"53","article-title":"Prognostic predictive value of 18F-fluorodeoxygucose positron emission tomography for patients with pancreatic cancer","volume":"19","author":"Nakata","year":"2001","journal-title":"Int J Oncol"},{"key":"10.1016\/j.adro.2024.101577_bib0038","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00534-006-1102-8","article-title":"Role of positron emission tomography in decisions on treatment strategies for pancreatic cancer","volume":"13","author":"Maemura","year":"2006","journal-title":"J Hepato-Bil Pancreat Surg"},{"key":"10.1016\/j.adro.2024.101577_bib0039","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/01.mcg.0000225672.68852.05","article-title":"The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer","volume":"40","author":"Bang","year":"2006","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.adro.2024.101577_bib0040","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.gassur.2003.09.002","article-title":"18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma","volume":"7","author":"Sperti","year":"2003","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.adro.2024.101577_bib0041","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1186\/s12885-023-11110-y","article-title":"Triple modal treatment comprising with proton beam radiation, hyperthermia, and gemcitabine\/nab-paclitaxel for locally advanced pancreatic cancer: A phase I\/II study protocol (TT-LAP trial)","volume":"23","author":"Shimomura","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.adro.2024.101577_bib0042","doi-asserted-by":"crossref","first-page":"644","DOI":"10.21037\/jgo.2016.05.06","article-title":"Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: A systematic review","volume":"7","author":"Verma","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.adro.2024.101577_bib0043","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ijrobp.2006.12.053","article-title":"Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer","volume":"68","author":"Murphy","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2024.101577_bib0044","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.ijrobp.2004.12.041","article-title":"Toxicities and effects of involved-field irradiation with concurrent cisplatin for unresectable carcinoma of the pancreas","volume":"62","author":"Kawakami","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2024.101577_bib0045","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00066-007-1641-1","article-title":"Concurrent chemoradiotherapy for advanced pancreatic cancer: 1000 mg\/m2 gemcitabine can be administered using limited field radiotherapy","volume":"183","author":"Yamazaki","year":"2007","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.adro.2024.101577_bib0046","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jso.21417","article-title":"Particle beam radiotherapy with a surgical spacer placement for advanced abdominal leiomyosarcoma results in a significant clinical benefit","volume":"101","author":"Fukumoto","year":"2010","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.adro.2024.101577_bib0047","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.3748\/wjg.v16.i14.1800","article-title":"Surgical spacer placement and proton radiotherapy for unresectable hepatocellular carcinoma","volume":"16","author":"Komatsu","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.adro.2024.101577_bib0048","first-page":"869","article-title":"Novel therapeutic strategy with particle radiotherapy for pancreatic cancer","volume":"32","author":"Matsumoto","year":"2011","journal-title":"J Biliary Tract Pancreas"},{"key":"10.1016\/j.adro.2024.101577_bib0049","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/jhbp.565","article-title":"Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatment","volume":"25","author":"Asano","year":"2018","journal-title":"J Hepatobilliary Pancreat Sci"},{"key":"10.1016\/j.adro.2024.101577_bib0050","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/jhbp.547","article-title":"Development of chemotherapy and significance of conversion surgery after chemotherapy in unresectable pancreatic cancer","volume":"25","author":"Furuse","year":"2018","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.adro.2024.101577_bib0051","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1118\/1.3187229","article-title":"The M. D. Anderson proton therapy system","volume":"36","author":"Smith","year":"2009","journal-title":"Med Phys"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109424001404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109424001404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T10:39:24Z","timestamp":1728988764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109424001404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2452109424001404"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2024.101577","relation":{},"ISSN":["2452-1094"],"issn-type":[{"value":"2452-1094","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Outcomes of Proton Beam Therapy for Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2024.101577","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101577"}}